Masimo Co. (NASDAQ:MASI) Shares Sold by APG Asset Management N.V.

APG Asset Management N.V. trimmed its position in Masimo Co. (NASDAQ:MASI) by 94.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,474 shares of the medical equipment provider’s stock after selling 179,726 shares during the period. APG Asset Management N.V.’s holdings in Masimo were worth $2,032,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Credit Agricole S A bought a new position in Masimo during the first quarter worth $29,000. Altshuler Shaham Ltd lifted its position in shares of Masimo by 91.0% in the 1st quarter. Altshuler Shaham Ltd now owns 170 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 81 shares during the last quarter. GQ Asset Management LLC acquired a new position in shares of Masimo in the 1st quarter valued at about $32,000. Huntington National Bank boosted its holdings in shares of Masimo by 124.5% in the 1st quarter. Huntington National Bank now owns 229 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 127 shares during the period. Finally, Procyon Private Wealth Partners LLC bought a new stake in shares of Masimo during the 4th quarter valued at about $54,000. 84.48% of the stock is owned by hedge funds and other institutional investors.

In other news, insider Jon Coleman sold 2,000 shares of the business’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $190.00, for a total value of $380,000.00. Following the sale, the insider now owns 14,465 shares of the company’s stock, valued at approximately $2,748,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Adam Mikkelson sold 1,498 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $216.01, for a total value of $323,582.98. Following the completion of the sale, the director now owns 2,802 shares of the company’s stock, valued at approximately $605,260.02. The disclosure for this sale can be found here. Insiders sold 351,114 shares of company stock valued at $68,294,418 over the last quarter. Insiders own 11.50% of the company’s stock.

Shares of MASI opened at $227.99 on Wednesday. Masimo Co. has a one year low of $139.36 and a one year high of $258.00. The stock’s fifty day moving average is $231.24 and its 200-day moving average is $191.19. The firm has a market capitalization of $11.89 billion, a price-to-earnings ratio of 61.79, a price-to-earnings-growth ratio of 3.19 and a beta of 0.91.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $0.97 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.06. Masimo had a net margin of 21.66% and a return on equity of 17.05%. The firm had revenue of $269.63 million for the quarter, compared to analysts’ expectations of $268.40 million. During the same quarter last year, the company earned $0.79 EPS. Masimo’s quarterly revenue was up 16.4% on a year-over-year basis. On average, research analysts expect that Masimo Co. will post 3.14 earnings per share for the current fiscal year.

A number of equities analysts have commented on MASI shares. ValuEngine downgraded Masimo from a “buy” rating to a “hold” rating in a research note on Friday, May 1st. UBS Group increased their target price on Masimo from $207.00 to $245.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Stifel Nicolaus boosted their price target on shares of Masimo from $200.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Raymond James restated a “buy” rating on shares of Masimo in a research report on Friday, June 26th. Finally, Needham & Company LLC downgraded shares of Masimo from a “buy” rating to a “hold” rating in a research report on Monday, April 20th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Masimo currently has an average rating of “Buy” and a consensus price target of $208.33.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Story: Insider Trading

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.